Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice

被引:12
作者
Li, Xiu-zhen [1 ,2 ]
Lv, Lin [1 ,2 ]
Zhang, Xu [3 ]
Anchang, Kenneth Yongabi [4 ]
Abdullahi, Auwalu Yusuf [1 ,2 ]
Tu, Liqing [1 ,2 ]
Wang, Xiaohu [5 ]
Xia, Lijun [1 ,2 ]
Zhang, Xiu-Xiang [6 ]
Feng, Weili [1 ,2 ]
Lu, Chunxia [2 ]
Li, Shoujun [1 ,2 ]
Yuan, Zi-Guo [1 ,2 ]
机构
[1] Guangdong Prov Key Lab Prevent & Control Severe C, 483 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China
[2] South China Agr Univ, Coll Vet Med, Guangzhou 510642, Guangdong, Peoples R China
[3] Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, Daqing 163319, Heilongjiang Pr, Peoples R China
[4] Catholic Univ Cameroon, Phytobiotechnol Res Fdn Inst PRF, Bamenda 999108, Cameroon
[5] Guangdong Acad Agr Sci, Inst Anim Hlth, Guangzhou 510642, Guangdong, Peoples R China
[6] South China Agr Univ, Coll Agr, Guangzhou 510642, Guangdong, Peoples R China
关键词
Toxoplasma gondii; Recombinant virus; CAV-2-ROP16; Vaccine; Mice; T-CELL RESPONSES; ADAPTIVE IMMUNE-RESPONSES; DEFICIENT MICE; DNA VACCINE; BALB/C MICE; IFN-GAMMA; IN-VIVO; VECTOR; INNATE; GENE;
D O I
10.1016/j.meegid.2016.10.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We previously demonstrated that the survival time of BALB/c mice challenged with Toxoplasma gondii RH strain was prolonged by immunising the mice with a eukaryotic vector expressing the protein ROP16 of T.gondii. Building upon previous findings, we are exploring improved vaccination strategies to enhance protection. In this work, a novel recombinant canine adenovirus type 2 expressing ROP16 (CAV-2-ROP16) of T. gondii was constructed and identified to express ROP16 in Madin-Darby canine kidney cells (MDCK) cells by western blot (WB) and indirect immunofluorescence (IFA) assays. Intramuscular immunisation of BALB/c mice with CAV-2-ROP16 was performed to evaluate the humoral and cellular immune responses. This vaccination triggered significant humoral and cellular responses, including ROP16-stimulated lymphoproliferation (P < 0.05). Compared to control groups, the CAV-2-ROP16 immunised mice had high production of IFN-gamma, IL-2 and IL-12 (P < 0.05), with a predominance of IgG2a production, but not IL-10 (P > 0.05), revealing that a predominant Th1-type response had developed. The cell-mediated cytotoxic activity with high levels of IFN-gamma and TNF-alpha was significantly increased in both CD4(+) and CD8(+) T-cell compartments in the mice immunised with CAV-2-ROP16 (P < 0.05), compared to three control groups. In addition, when immunised mice were challenged with the RH strain of T.gondii, they showed a significantly increased survival rate (25%) 80 days post infection compared with control mice that all died within seven days (P < 0.05). The 25% protection rate elicited by the recombinant virus CAV-2-ROP16 has not been achieved in the field of anti-T.gondii vaccination until now. Our work presents the successful use of recombinant virus CAV-2-ROP16 in vaccination protocols to protect against intraperitoneal challenge with the virulent RH strain of T.gondii. This system was shown to be extremely efficient in eliciting humoral and cellular immune responses that led to a significant improvement in survival time in mice. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:447 / 453
页数:7
相关论文
共 43 条
  • [1] Vaccination greatly reduces disease, disability, death and inequity worldwide
    Andre, F. E.
    Booy, R.
    Bock, H. L.
    Clemens, J.
    Datta, S. K.
    John, T. J.
    Lee, B. W.
    Lolekha, S.
    Peltola, H.
    Ruff, T. A.
    Santosham, M.
    Schmitt, H. J.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (02) : 140 - 146
  • [2] TRIF, and TRIF-Interacting TLRs Differentially Modulate Several Adenovirus Vector-Induced Immune Responses
    Appledorn, D. M.
    Patial, S.
    Godbehere, S.
    Parameswaran, N.
    Amalfitano, A.
    [J]. JOURNAL OF INNATE IMMUNITY, 2009, 1 (04) : 376 - 388
  • [3] Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo
    Appledorn, Daniel M.
    Patial, Sonika
    McBride, Aaron
    Godbehere, Sarah
    Van Rooijen, Nico
    Parameswaran, Narayanan
    Amalfitano, Andrea
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 181 (03) : 2134 - 2144
  • [4] Vaccination with an Adenoviral Vector That Encodes and Displays a Retroviral Antigen Induces Improved Neutralizing Antibody and CD4+ T-Cell Responses and Confers Enhanced Protection
    Bayer, Wibke
    Tenbusch, Matthias
    Lietz, Ruth
    Johrden, Lena
    Schimmer, Simone
    Ueberla, Klaus
    Dittmer, Ulf
    Wildner, Oliver
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (04) : 1967 - 1976
  • [5] CD8+-T-cell immunity against Toxoplasma gondii can be induced but not maintained in mice lacking conventional CD4+ T cells
    Casciotti, L
    Ely, KH
    Williams, ME
    Khan, IA
    [J]. INFECTION AND IMMUNITY, 2002, 70 (02) : 434 - 443
  • [6] Toxoplasma gondii: Protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis
    Chen, Jia
    Zhou, Dong-Hui
    Li, Zhong-Yuan
    Petersen, Eskild
    Huang, Si-Yang
    Song, Hui-Qun
    Zhu, Xing-Quan
    [J]. EXPERIMENTAL PARASITOLOGY, 2014, 139 : 42 - 48
  • [7] Evaluation of Immunoprotection Conferred by the Subunit Vaccines of GRA2 and GRA5 against Acute Toxoplasmosis in BALB/c Mice
    Ching, Xiao T.
    Fong, Mun Y.
    Lau, Yee L.
    [J]. FRONTIERS IN MICROBIOLOGY, 2016, 7
  • [8] Parasite vaccines: The new generation
    Crampton, A.
    Vanniasinkam, T.
    [J]. INFECTION GENETICS AND EVOLUTION, 2007, 7 (05) : 664 - 673
  • [9] Viruses as vaccine vectors for infectious diseases and cancer
    Draper, Simon J.
    Heeney, Jonathan L.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2010, 8 (01) : 62 - 73
  • [10] Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes
    Gao, Guangping
    Wang, Qiang
    Dai, Zhiyan
    Calcedo, Roberto
    Sun, Xun
    Li, Gang
    Wilson, James M.
    [J]. HUMAN GENE THERAPY, 2008, 19 (09) : 927 - 936